NTRS
49
-3
NOC
61
-3
CRM
37
-3
AN
44
-6
MUR
65
3
NWL
41
8
CFG
54
14
UAL
48
-3
GPS
46
4
ORLY
66
10
AAL
61
-4
JNJ
51
-2
NOV
58
4
GS
49
-3
C
34
-3
NAVI
55
-5
KO
42
-2
ESS
39
-5
WMT
59
-3
EIX
45
-2
NTRS
49
-3
NOC
61
-3
CRM
37
-3
AN
44
-6
MUR
65
3
NWL
41
8
CFG
54
14
UAL
48
-3
GPS
46
4
ORLY
66
10
AAL
61
-4
JNJ
51
-2
NOV
58
4
GS
49
-3
C
34
-3
NAVI
55
-5
KO
42
-2
ESS
39
-5
WMT
59
-3
EIX
45
-2
Financhill
Back

Actinium Pharmaceuticals Quote, Financials, Valuation and Earnings

Buy
75

ATNM
Actinium Pharmaceuticals

Last Price:
7.94
Seasonality Move:
-1.21%

7 Day Trial

ALL ACCESS PASS

$ 7

Actinium Pharmaceuticals Price Quote

$7.94

Actinium Pharmaceuticals Key Stats

Buy
75
Actinium Pharmaceuticals (ATNM) is a Buy
Day range:
$7.57 - $8.03
52-week range:
$4.41 - $9.21
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
143.53
P/B ratio:
2.56%
Volume:
144.3K
Avg. volume:
188.4K
1-year change:
-4.8%
Market cap:
$200M
Revenue:
$1.1M
EPS:
$-1.22

How Much Does Actinium Pharmaceuticals Make?

Is Actinium Pharmaceuticals Growing As A Company?

Actinium Pharmaceuticals Stock Price Performance

What Is Actinium Pharmaceuticals 52-Week High & Low?

Actinium Pharmaceuticals Price To Free Cash Flow

Is It Risky To Buy Actinium Pharmaceuticals?

Is Actinium Pharmaceuticals Cash Flow Positive?

  • What Is ATNM Cash Flow From Operations?
    Cash flow from operations (TTM) is $11.5M
  • What Is Actinium Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $23.2M
  • What Is Actinium Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$345K

Actinium Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    ATNM return on invested capital is -35.83%
  • What Is Actinium Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -30.66%
  • What Is ATNM Return On Equity?
    ROE is a measure of profitability and is -35.83%

Actinium Pharmaceuticals Earnings Date & Stock Price

Actinium Pharmaceuticals Competitors

Actinium Pharmaceuticals Dividend Yield

Data Unavailable

Actinium Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -43.48%
Revenue: -83.08% -95.14%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 23.23
Upside from Last Price: 192.59%

Major Shareholders

  • How many ATNM shares are owned by institutional investors?
    3.9M ATNM shares are owned by institutional investors
  • How many ATNM shares are owned by insiders?
    572.8K ATNM shares are owned by insiders